Agenus (AGEN) is reallocating development and financial resources toward a Phase 3 registrational trial of neoadjuvant BOT/BAL (botensilimab + balstilimab) in high-risk stage 2/3 microsatellite-stable colon cancer. The shift in focus signals an attempt to advance toward registrational data and potential regulatory milestones.
Agenus (AGEN) is reallocating development and financial resources toward a Phase 3 registrational trial of neoadjuvant BOT/BAL (botensilimab + balstilimab) in high-risk stage 2/3 microsatellite-stable colon cancer. The shift in focus signals an attempt to advance toward registrational data and potential regulatory milestones.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.10
Ticker Sentiment
